文献速递精神分裂症与精神病性障碍

精神分裂症中的补体系统:现状与未来方向

The complement system in schizophrenia: where are we now and what's next?
PubMed 文献 · Mol Psychiatry · 2019-08-22

本文更新并评论了精神分裂症与补体基因多态性、基因表达、蛋白浓度及通路活性关系的文献,发现自2008年首篇综述以来新增23项研究;总体补体通路活性在精神分裂症中似乎升高,C4与CSMD1为潜在遗传标志物,但文献存在样本量小等方法学局限。

要点

  • 精神分裂症患者总体补体通路活性似乎升高。
  • C4与CSMD1为潜在遗传标志物,C4B/C4S缺陷率较高、外周C4B浓度降低、脑C4A mRNA表达升高。
  • 补体成分尤其C4和CSMD1为潜在新药靶点,但现有文献样本量小、方法不一致。

核心结论

  • 近期证据提示补体通路活性在精神分裂症中升高,C4和CSMD1为潜在遗传标志物及新药靶点。

研究设计与样本

  • 本文为叙述性综述与文献评论,检索2008年首篇综述后新增的23项研究,并采用MAGMA进行基因与基因集分析。

主要发现

  • 精神分裂症患者中补体通路活性似乎总体升高。
  • 有证据提示精神分裂症患者C4B/C4S缺陷率较高、外周C4B浓度降低、脑C4A mRNA表达升高。
  • MAGMA分析支持HLA III类基因及较弱程度上CSMD1与精神分裂症的关联,但HLA关联可能由C4驱动。

关键数值与推荐

  • 文献检索识别出2008年首篇综述后新增23项研究。
  • MAGMA基因与基因集分析支持HLA III类基因及较弱程度上CSMD1与精神分裂症的关联。

临床怎么用

  • 补体成分尤其C4和CSMD1为潜在新药靶点,未来可评估补体靶向疗法对精神分裂症的疗效。

局限性

  • 现有文献样本量小、方法学不一致。
  • 补体蛋白神经浓度测量有限。
  • 补体与精神分裂症表型关联探索不足。
  • 缺乏探索精神分裂症治疗反应的研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The complement system is a set of immune proteins involved in first-line defense against pathogens and removal of waste materials. Recent evidence has implicated the complement cascade in diseases involving the central nervous system, including schizophrenia. Here, we provide an up-to-date narrative review and critique of the literature on the relationship between schizophrenia and complement gene polymorphisms, gene expression, protein concentration, and pathway activity. A literature search identified 23 new studies since the first review on this topic in 2008. Overall complement pathway activity appears to be elevated in schizophrenia. Recent studies have identified complement component 4 (C4) and CUB and Sushi Multiple Domains 1 (CSMD1) as potential genetic markers of schizophrenia. In particular, there is some evidence of higher rates of C4B/C4S deficiency, reduced peripheral C4B concentration, and elevated brain C4A mRNA expression in schizophrenia patients compared to controls. To better elucidate the additive effects of multiple complement genotypes, we also conducted gene- and gene-set analysis through MAGMA which supported the role of Human Leukocyte Antigen class (HLA) III genes and, to a lesser extent, CSMD1 in schizophrenia; however, the HLA-schizophrenia association was likely driven by the C4 gene. Lastly, we identified several limitations of the literature on the complement system and schizophrenia, including: small sample sizes, inconsistent methodologies, limited measurements of neural concentrations of complement proteins, little exploration of the link between complement and schizophrenia phenotype, and lack of studies exploring schizophrenia treatment response. Overall, recent findings highlight complement components-in particular, C4 and CSMD1-as potential novel drug targets in schizophrenia. Given the growing availability of complement-targeted therapies, future clinical studies evaluating their efficacy in schizophrenia hold the potential to accelerate treatment advances.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Woo JJ, Pouget JG, Zai CC, et al. The complement system in schizophrenia: where are we now and what's next? Mol Psychiatry. 2019. PMID: 31439935. doi:10.1038/s41380-019-0479-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。